Oxycodone-Induced Neuropsychiatric Side Effects

Introduction to Oxycodone Side Effects

Oxycodone can cause hallucinations and nightmares as recognized side effects, particularly as manifestations of opioid-induced neurotoxicity, as noted by the British Journal of Cancer 1, 2

Hallucinations and nightmares are known adverse effects of oxycodone, though they occur less frequently than common side effects like constipation, nausea, and drowsiness, according to the British Journal of Cancer 3
These neuropsychiatric symptoms are part of a spectrum of opioid-induced neurotoxicity that can also include delirium, cognitive impairment, and myoclonus, as reported by Praxis Medical Insights 2

Neuropsychiatric side effects are more likely to occur during treatment initiation or dose titration phases, as noted by the British Journal of Cancer 3
Rapid dose escalation is also a risk factor for neuropsychiatric side effects, according to Praxis Medical Insights 2
Accumulation of metabolites in patients with renal or hepatic impairment can increase the risk of neuropsychiatric side effects, as reported by Praxis Medical Insights and the British Journal of Cancer 2, 3
High-dose opioid therapy is also a risk factor for neuropsychiatric side effects, according to the British Journal of Cancer 1

Dose reduction can be considered if pain is well-controlled, as noted by the British Journal of Cancer 3, 1
Opioid rotation to a different opioid, such as fentanyl, can be considered if hallucinations persist despite dose adjustment, according to the British Journal of Cancer and Praxis Medical Insights 1, 2

Patients should be informed about the possibility of hallucinations and nightmares when starting oxycodone therapy, as recommended by the British Journal of Cancer 3
Patients with a history of opioid-induced neurotoxicity require closer monitoring, as they are at higher risk for recurrence, according to Praxis Medical Insights 2
Patients with renal insufficiency require special caution due to potential accumulation of metabolites, as reported by Praxis Medical Insights and the British Journal of Cancer 2, 3